| scholarly article | Q13442814 |
| P50 | author | Justine Smith | Q71908832 |
| P2093 | author name string | J T Rosenbaum | |
| K B Baker | |||
| N J Spurrier | |||
| A S Watkins | |||
| P2860 | cites work | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| A role for methotrexate in the management of non-infectious orbital inflammatory disease | Q28360294 | ||
| Cyclosporin therapy for severe scleritis | Q33647451 | ||
| Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. | Q33920749 | ||
| A controlled trial of azathioprine in Behçet's syndrome | Q34656107 | ||
| Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. | Q41917077 | ||
| Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone | Q41939160 | ||
| Drugs to treat inflammation: a historical introduction | Q41946179 | ||
| Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation | Q43875370 | ||
| Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. | Q44549604 | ||
| Low-dose methotrexate therapy for ocular inflammatory disease | Q45693995 | ||
| Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings | Q46416659 | ||
| Noninfectious uveitis: a scarcity of randomized clinical trials | Q46481530 | ||
| A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. | Q46595124 | ||
| Mycophenolate mofetil therapy for inflammatory eye disease | Q46629616 | ||
| Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder | Q46702085 | ||
| Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients | Q46703867 | ||
| Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis | Q47343514 | ||
| Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. | Q51032239 | ||
| Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis | Q67938095 | ||
| Oral cyclophosphamide in the treatment of uveitis | Q71448880 | ||
| Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management | Q72051049 | ||
| Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients | Q73947310 | ||
| Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series | Q81722873 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1481-1485 | |
| P577 | publication date | 2006-08-16 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease | |
| P478 | volume | 90 |
| Q41614992 | Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease |
| Q38197504 | Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. |
| Q37204512 | Methotrexate for ocular inflammatory diseases |
| Q36919959 | Role of the retinal vascular endothelial cell in ocular disease |
Search more.